Neovacs Statistics

Total Valuation

Neovacs has a market cap or net worth of EUR 6,209. The enterprise value is -198,872.

Market Cap	6,209
Enterprise Value	-198,872

Important Dates

The last earnings date was Wednesday, June 4, 2025.

Earnings Date	Jun 4, 2025
Ex-Dividend Date	n/a

Share Statistics

Neovacs has 2.07 million shares outstanding.

Current Share Class	2.07M
Shares Outstanding	2.07M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	n/a

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.01
PB Ratio	0.00
P/TBV Ratio	0.00
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	0.01
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	0.05

Financial Position

The company has a current ratio of 0.64, with a Debt / Equity ratio of 0.01.

Current Ratio	0.64
Quick Ratio	0.62
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	-0.06
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -98.39% and return on invested capital (ROIC) is -12.21%.

Return on Equity (ROE)	-98.39%
Return on Assets (ROA)	-11.09%
Return on Invested Capital (ROIC)	-12.21%
Return on Capital Employed (ROCE)	-36.33%
Revenue Per Employee	21,697
Profits Per Employee	-1.65M
Employee Count	20
Asset Turnover	0.01
Inventory Turnover	n/a

Taxes

Income Tax	-1.03M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -100.00% in the last 52 weeks. The beta is -136.92, so Neovacs's price volatility has been lower than the market average.

Beta (5Y)	-136.92
52-Week Price Change	-100.00%
50-Day Moving Average	0.01
200-Day Moving Average	1.36
Relative Strength Index (RSI)	41.45
Average Volume (20 Days)	42,381,239

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Neovacs had revenue of EUR 433,937 and -32.91 million in losses. Loss per share was -188.61.

Revenue	433,937
Gross Profit	-2.77M
Operating Income	-6.62M
Pretax Income	-33.95M
Net Income	-32.91M
EBITDA	-6.43M
EBIT	-6.62M
Loss Per Share	-188.61

Full Income Statement

Balance Sheet

The company has 435,449 in cash and 230,367 in debt, giving a net cash position of 205,082 or 0.10 per share.

Cash & Cash Equivalents	435,449
Total Debt	230,367
Net Cash	205,082
Net Cash Per Share	0.10
Equity (Book Value)	18.06M
Book Value Per Share	103.50
Working Capital	-1.37M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -3.60 million and capital expenditures -79,706, giving a free cash flow of -3.68 million.

Operating Cash Flow	-3.60M
Capital Expenditures	-79,706
Free Cash Flow	-3.68M
FCF Per Share	-1.78

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-1,525.96%
Pretax Margin	-7,823.36%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Neovacs does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-530,108.05%
FCF Yield	-59,283.72%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on December 5, 2024. It was a reverse split with a ratio of 0.0001.

Last Split Date	Dec 5, 2024
Split Type	Reverse
Split Ratio	0.0001

Scores

Neovacs has an Altman Z-Score of -4.84 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-4.84
Piotroski F-Score	3